| Name | Title | Contact Details |
|---|
Visit the home page of the Shakopee Mdewakanton Sioux Community. Explore and learn about the remarkable people building a bright future in Scott County, MN.
CANUSAMEX Inc. is a Spring, TX-based company in the Business Services sector.
Property Management & Investment in Austin, Texas
Staffing shortage across the healthcare ecosystem is taking its toll on nursing staff and caregivers. In addition, the desire to shift towards home-based care, especially in rural areas, has driven the need for a better remote patient monitoring platform and patient experience. Current solutions lack a frictionless experience for both the patient and clinician, as they often only offer spot checks and require patients to manipulate devices or receive caregiver assistance. This can be problematic for the elderly, cognitively or motor impaired individuals. Neteeras technology addresses these needs with a continuous, contactless, passive vital signs, and bio-data monitoring solution. Our FCC, HIPAA and GDPR compliant solution seamlessly and safely facilitates rapid and accurate remote patient monitoring in real-time. Neteeras sensing platform eliminates the need for device manipulation, removal of clothing, and caregiver presence. Neteeras technology is a maintenance-free, radar-based solution that is non-intrusive as it does not rely on images. We can improve care and ultimately reduce healthcare costs and enable optimal comfort for the patients as their involvement is not required. Neteera was founded in 2015 by a group of hi-tech veteran executives, including Isaac Litman, the CEO of Mobileye (NYSE: MBLY) Aftermarket.
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.